| Literature DB >> 27185415 |
Sayak Mukhopadhyay1, Rohini Saha1, Anbarasi Palanisamy1, Madhurima Ghosh1, Anupriya Biswas2, Saheli Roy2, Arijit Pal1, Kathakali Sarkar1, Sangram Bagh1.
Abstract
Microgravity is a prominent health hazard for astronauts, yet we understand little about its effect at the molecular systems level. In this study, we have integrated a set of systems-biology tools and databases and have analysed more than 8000 molecular pathways on published global gene expression datasets of human cells in microgravity. Hundreds of new pathways have been identified with statistical confidence for each dataset and despite the difference in cell types and experiments, around 100 of the new pathways are appeared common across the datasets. They are related to reduced inflammation, autoimmunity, diabetes and asthma. We have identified downregulation of NfκB pathway via Notch1 signalling as new pathway for reduced immunity in microgravity. Induction of few cancer types including liver cancer and leukaemia and increased drug response to cancer in microgravity are also found. Increase in olfactory signal transduction is also identified. Genes, based on their expression pattern, are clustered and mathematically stable clusters are identified. The network mapping of genes within a cluster indicates the plausible functional connections in microgravity. This pipeline gives a new systems level picture of human cells under microgravity, generates testable hypothesis and may help estimating risk and developing medicine for space missions.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27185415 PMCID: PMC4868995 DOI: 10.1038/srep25975
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1GSEA analysis of human cell during microgravity exposure.
(a) Genome wide expression profile of E-GEOD-4209 for three biological replicates in microgravity and normal gravity. The heatmap represents ranked genes, which is created by signal-to-noise matric (fold change in expression between microgravity and normal gravity divided by the standard deviation in gene expression among the replicates). (b) Enrichment score of four representative, statistically significant pathways from four different gene set modules. The top and bottom figures represent upregulated and downregulated pathways respectively. The heatmap of the ranked gene list is shown at the bottom of each pathway. The black lines within the heatmap represent the position of the pathway genes in that ranked list.
Figure 2Number of statistically significant (p < 0.001, q < 0.001) altered molecular pathways identified by GSEA on different studies.
Each bar chart represents one of the eight gene set modules from molecular signature database (MSigDB).
Figure 3Venn diagrams represent the common altered pathways in microgravity for (a) upregulated pathways and (b) downregulated pathways. All altered pathways from 8 gene set modules are combined in this diagram.
Microgravity induced functions are supported by multiple molecular pathways.
| Repressed immunity | KEGG intestinal immune network for IGA production; Biocarta inflame pathway; Biocarta cytokine pathway; KEGG cytokine cytokine receptor interaction; PID NFAT TF pathway; Zhou inflammatory response live up; Vilimas Notch1 targets up; Goldrath antigen response; Hallmark TNFA signaling via NFκB; GSE17721 0.5 h Vs 4 h CPG BMDM up; GSE3982 B cell Vs EFF memory CD4 T-cell up;Biocarta NKT pathway; Reactome second messenger molecules signaling pathway | |
| Reduced inflammatory response | Biocarta inflame pathway; Galindo immune response to enterotoxin; Tian TNF signaling not via NFκB; Seki inflammatory response LPS up; GSE9988 LPS Vs LPS and anti TREM1 monocyte dn; GSE14000 unstim Vs 16 h LPS DC up | |
| Repressed autoimmunity signature | KEGG allograft rejection; KEGG autoimmune thyroid disease; KEGG graft Vs host disease; KEGG TypeI diabetis mellitus; Reactome PD1 signaling | |
| Reduction in LPS induced gene expression | GSE9988 LPS_Vs vehicle treated monocyte up;_GSE2706 unstim Vs 2 h LPS DC dn; GSE9988 low LPS Vs vehicle treated monocyte up; GSE9988 low LPS Vs ctrl treated monocyte up; LOW_LPS_VS_CTRL_TREATED_MONOCYTE_UP, GSE9988_LPS_VS_CTRL_TREATED_MONOCYTE_UP, SEKI_INFLAMMATORY_RESPONSE_LPS_UP | |
| Blood cell differentiation signature (inhibition) | Mori mature B lymphocyte up; Oswald hematopoetic stem cell in collagen gel up; Basso CD40 signaling up | |
| Induced liver cancer | Module 75; Module 46 | |
| Induced B Lymphoma, diffuse large B cell lymphoma, leukaemia | Module 47 | Module 6; Module 123; Verhaak AML with NPM1 mutated dn |
| Induced Lung carcinoid and reduced pro-survival | Phong TNF tergets up | |
| ESR positive breast cancer | Doane breast cancer ESR1 dn | |
| Induction of Head and Neck cancer | Rickman head and neck cancer C | |
| Oncogenic signature | KRAS300_UP.V1_UP; KRAS600_UP.V1_UP | Amit delayed early genes |
| Ovarian cancer growth | Lu EZH2 targets up | |
| Increased responsiveness to cancer treatment | Heller HDAC Targets silenced by methylation up | Kobayashi EGFR signaling 6 hr dn; Becker Tamoxifen resistance up; Peng Rapamycin response dn, Lee liver cancer survival dn |
| Induction of apoptosis | GSE37416 CTRL Vs 12 h F Tularessis L Vs neutrophil dn; Brocke apoptosis reversed by IL6; Dairkee TERT targets up | |
| Reduced asthma signature | Bosco epithelial differentiation module | KEGG asthma |
| Reduced diabetes signature | Servitja islet HNF1A targets dn | KEGG Type I diabetes mellitus; GSE9006 healthy Vs type 2 diabetes PBMC at DX up |
| Psychiatric | Kim all disorders duration corr dn; Stark prefrontal cortex 22Q11 deletion dn | |
| Reduced oxidative phosphorylation | Reactome TCA cycle; Reactome respiratory electron transport; ATP synthesis by chemiosmotic coupling and heat produced by uncoupling protein; Module152; Mootha VOXPHOS; Hallmark oxidative phosphorylation | |
| Reduced post transcription | Module 114; Reactome mRNA processing; LI DCP2 bound mRNA | |
| Increased SLC-mediated transmembrane transport | Reactome SLC mediated transmembrane transport | |
*The description of the gene sets can be found in Supplementary Table 2.
Figure 4Consensus non-negative matrix factorization (NMFC) clustering on leading edge genes.
(a) Cophenetic coefficient as a function of number of clusters for downregulated leading edge genes from canonical pathways for E-GEOD-38836. The arrow indicates the maximum number of mathematically stable clusters possible in this example. (b) Maximum number of mathematically stable clusters plausible for other experiments. Clusters with upregulated and downregulated genes are shown in black and red bars respectively.
Figure 5Protein-protein association (PPA) networks.
Networks (a–f) represent NMFC clusters from various datasets of downregulated genes from canonical pathways in microgravity. Each node represents a protein and the line connecting the nodes (edge) represents the functional association. The relative thickness of each line signifies the confidence level of such association.